Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman
E
E
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Raymond
V
V
Gee
T
T
Kempin
S J
SJ
Gulati
S
S
Andreeff
M
M
Kolitz
J
J
Gabrilove
J
J
Heller
G
G
Young
C W
CW
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000009:adverse effects; D007938:Leukemia / Q000188:drug therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction
D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin